Search research articles
Contact Us
Filters
Showing results (31-40 of 93) with videos related to
Page
of 10
Sort By:
Haematologica
|
March 28, 2024
BCMA x CD3 T-cell engager in a patient with pentarefractory multiple myeloma and HIV: a clinical and immunological report
Leon Cords, Christoph Schaefers, Abdulaziz Kamili, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 23, 2025
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review
Shaji Kumar, Xavier Leleu, Katja C Weisel, et al.
Leukemia
|
April 25, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
Hartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, et al.
Leukemia & Lymphoma
|
August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
Xiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Hemasphere
|
July 17, 2025
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma
Ola Landgren, Noa Biran, Elizabeth K O'Donnell, et al.
Leukemia & Lymphoma
|
February 10, 2010
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas
Eckhart Weidmann, Georg Hess, Kai U Chow, et al.
Cancers
|
September 28, 2023
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Lisa B Leypoldt, Maria Gavriatopoulou, Britta Besemer, et al.
Clinical and Translational Science
|
June 26, 2020
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
Xiaoyu Yan, Xu Steven Xu, Katja C Weisel, et al.
Clinical Pharmacology : Advances and Applications
|
November 30, 2017
Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
Yan Li, Xiaomin Wang, Edward O'Mara, et al.
Blood Cancer Journal
|
April 10, 2019
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
Katja C Weisel, Christof Scheid, Manola Zago, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 93) with videos related to
Sort By:
Page
of 10
Haematologica
|
March 28, 2024
BCMA x CD3 T-cell engager in a patient with pentarefractory multiple myeloma and HIV: a clinical and immunological report
Leon Cords, Christoph Schaefers, Abdulaziz Kamili, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 23, 2025
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review
Shaji Kumar, Xavier Leleu, Katja C Weisel, et al.
Leukemia
|
April 25, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
Hartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, et al.
Leukemia & Lymphoma
|
August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
Xiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Hemasphere
|
July 17, 2025
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma
Ola Landgren, Noa Biran, Elizabeth K O'Donnell, et al.
Leukemia & Lymphoma
|
February 10, 2010
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas
Eckhart Weidmann, Georg Hess, Kai U Chow, et al.
Cancers
|
September 28, 2023
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Lisa B Leypoldt, Maria Gavriatopoulou, Britta Besemer, et al.
Clinical and Translational Science
|
June 26, 2020
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
Xiaoyu Yan, Xu Steven Xu, Katja C Weisel, et al.
Clinical Pharmacology : Advances and Applications
|
November 30, 2017
Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
Yan Li, Xiaomin Wang, Edward O'Mara, et al.
Blood Cancer Journal
|
April 10, 2019
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
Katja C Weisel, Christof Scheid, Manola Zago, et al.
Page
of 10